lipid-a and Mast-Cell-Sarcoma

lipid-a has been researched along with Mast-Cell-Sarcoma* in 2 studies

Other Studies

2 other study(ies) available for lipid-a and Mast-Cell-Sarcoma

Article	Year
Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. European cytokine network, 1999, Volume: 10, Issue:2 Immunization of cancer patients with tumor-specific antigenic peptides is currently being tested in several clinical studies. We have examined the induction of CTL responses in mice after various modalities of peptide vaccination, to explore protocols that could be applied to humans. Our first model antigen was P198, which results from a point mutation in a normal gene. While two immunizations with peptide P198 in SBAS-1c adjuvant induced measurable CTL responses in less than 10% of DBA/2 mice, the addition of IL-12 to the peptide adjuvant mixture resulted in high CTL responses in nearly all mice. This strong enhancing effect of IL-12 was observed with 1,000 and 300 units and decreased gradually as the doses were reduced to 30 units. When IL-12 was replaced by other cytokines acting on T cells or antigen-presenting cells, such as IFN-gamma, IL-2, IL-6, IL-7, GM-CSF or MCP-3, no significant enhancing effect was observed. The same effect of IL-12 was obtained with peptide P1A, which is a major tumor-specific antigen of mastocytoma P815 and is encoded by a gene that is specifically activated in tumors. Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Cancer Vaccines; Cytotoxicity Tests, Immunologic; Drug Synergism; Ear, External; Female; H-2 Antigens; Hindlimb; Histocompatibility Antigens; Immunotherapy, Active; Injections, Subcutaneous; Interferon-gamma; Interleukin-12; Lipid A; Lymphocyte Activation; Mast-Cell Sarcoma; Mice; Mice, Inbred DBA; Organ Specificity; Peptide Fragments; Saponins; Specific Pathogen-Free Organisms; T-Lymphocytes, Cytotoxic; Tail; Tumor Cells, Cultured	1999
Analysis of the lipopolysaccharide-induced cytostatic activity of macrophages, by the use of synthetic models. Cellular immunology, 1986, Volume: 98, Issue:1 Informations on the structural features implicated in the macrophage-dependent cytostatic activity of "lipid A" preparations were obtained by the use of 15 synthetic glycolipids. Four structural requirements were identified: the presence of a reducing glucosamine unit; the presence of a free hydroxyl group on amide-linked 3-hydroxytetradecanoic acids, and the absence of free hydroxyl groups at positions 3 and 6 of the glucosamine. The monosaccharide resembling the reducing unit of the "lipid A backbone," which fulfills these criteria, had the highest cytostatic activity, whereas the compound possessing the substitution pattern of the nonreducing moiety was inactive. Topics: Animals; Cell Division; Cytotoxicity, Immunologic; Disaccharides; Endotoxins; Glycolipids; Lipid A; Lipopolysaccharides; Macrophages; Male; Mast-Cell Sarcoma; Mice; Mice, Inbred C3H; Models, Biological; Monosaccharides; Polymyxin B; Virulence Factors, Bordetella	1986

Article

Year

Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.

European cytokine network, 1999, Volume: 10, Issue:2

Immunization of cancer patients with tumor-specific antigenic peptides is currently being tested in several clinical studies. We have examined the induction of CTL responses in mice after various modalities of peptide vaccination, to explore protocols that could be applied to humans. Our first model antigen was P198, which results from a point mutation in a normal gene. While two immunizations with peptide P198 in SBAS-1c adjuvant induced measurable CTL responses in less than 10% of DBA/2 mice, the addition of IL-12 to the peptide adjuvant mixture resulted in high CTL responses in nearly all mice. This strong enhancing effect of IL-12 was observed with 1,000 and 300 units and decreased gradually as the doses were reduced to 30 units. When IL-12 was replaced by other cytokines acting on T cells or antigen-presenting cells, such as IFN-gamma, IL-2, IL-6, IL-7, GM-CSF or MCP-3, no significant enhancing effect was observed. The same effect of IL-12 was obtained with peptide P1A, which is a major tumor-specific antigen of mastocytoma P815 and is encoded by a gene that is specifically activated in tumors.

Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Cancer Vaccines; Cytotoxicity Tests, Immunologic; Drug Synergism; Ear, External; Female; H-2 Antigens; Hindlimb; Histocompatibility Antigens; Immunotherapy, Active; Injections, Subcutaneous; Interferon-gamma; Interleukin-12; Lipid A; Lymphocyte Activation; Mast-Cell Sarcoma; Mice; Mice, Inbred DBA; Organ Specificity; Peptide Fragments; Saponins; Specific Pathogen-Free Organisms; T-Lymphocytes, Cytotoxic; Tail; Tumor Cells, Cultured

1999

Analysis of the lipopolysaccharide-induced cytostatic activity of macrophages, by the use of synthetic models.

Cellular immunology, 1986, Volume: 98, Issue:1

Informations on the structural features implicated in the macrophage-dependent cytostatic activity of "lipid A" preparations were obtained by the use of 15 synthetic glycolipids. Four structural requirements were identified: the presence of a reducing glucosamine unit; the presence of a free hydroxyl group on amide-linked 3-hydroxytetradecanoic acids, and the absence of free hydroxyl groups at positions 3 and 6 of the glucosamine. The monosaccharide resembling the reducing unit of the "lipid A backbone," which fulfills these criteria, had the highest cytostatic activity, whereas the compound possessing the substitution pattern of the nonreducing moiety was inactive.

Topics: Animals; Cell Division; Cytotoxicity, Immunologic; Disaccharides; Endotoxins; Glycolipids; Lipid A; Lipopolysaccharides; Macrophages; Male; Mast-Cell Sarcoma; Mice; Mice, Inbred C3H; Models, Biological; Monosaccharides; Polymyxin B; Virulence Factors, Bordetella

1986